MicroRNA-based targeted therapeutics in pancreatic cancer

Nilgun Gurbuz, Bulent Ozpolat

Research output: Contribution to journalReview articlepeer-review

30 Scopus citations


The discovery during the last decade of microRNAs (miRs, miRNA) and their role in regulating normal physiological processes as well as in the pathogenesis of human tumors has been a revolutionary development in molecular oncology. miRNAs activating or inhibiting oncogenic molecular pathways that are involved in tumorigenesis, cell progression, invasion, angiogenesis and metastasis are now considered of major impact in many cancer types. miRNA-based therapeutics that inhibit the levels of oncogenic miRNAs (oncomiRs) or elevate tumor suppressor miRs have enormous potential as molecular therapeutic targets. Thus, the development of new targeted cancer therapies based on miRNAs promise to revolutionize cancer treatment due to their increased efficacy compared to conventional chemoradiation-based therapies and hopefully to lower levels of adverse effects.

Original languageEnglish (US)
Pages (from-to)529-532
Number of pages4
JournalAnticancer Research
Issue number2
StatePublished - Feb 2019


  • Clinical trial
  • MiRNA
  • Nanoparticle
  • Pancreatic cancer
  • Review
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'MicroRNA-based targeted therapeutics in pancreatic cancer'. Together they form a unique fingerprint.

Cite this